Issues

ABOUT THE COVER
Hippo pathway signaling through hyperactivated YAP has been shown to promote aggressive phenotypes in uveal melanoma, but its role in cutaneous melanoma is poorly understood. In this issue, Zhang and colleagues demonstrate that YAP is upregulated and hyperactivated in most premalignant melanocytic nevi and malignant melanoma lesions, and it presents a potential therapeutic target in a subset of melanoma patients. Moreover, the authors provide clinical evidence for the first known activating YAP mutations in human cancer. See the article beginning on page 1435 for more information.
The cover depicts co-immunofluorescence staining of a clinical case of cutaneous melanoma (red, Melan-A; green, YAP1; blue, nuclei stained with DAPI).